Pharmacological Treatment of Presbyopia
- Registration Number
- NCT05564832
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
In this clinical trial, a total of 75 presbyopic patients in the age range of 40 to 60 years old will be participated. The right eyes of 45 patients will be treated by Biocarpine® and they will be considered as the case group, their left eyes will be defined as the controls. In another case group, the right eyes of 30 patients will received Vuity® eye drops and their left eyes will be considered as controls.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 75
- Subjects with the best corrected visual acuity (BCVA) better than 0.3LogMAR
- Patients with the symptom of blurred vision at near distance
Patients with amblyopia, cataract, corneal opacity, glaucoma, intraocular surgery, eye troma, congenital pupil anomalies and those with the history of headache and allergy to the eye drop will be excluded from the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pilocarpine Therapy Pilocarpine 1.25% Eye drop The right eyes of 45 patients will be treated by Biocarpine® and Vuity® eye drops. They will be considered as the case group,
- Primary Outcome Measures
Name Time Method The changes of near vision after one hour following pilocarpine eye drop baseline to one hour after pilocarpine insillation The near vision will be measured based on the LogMAR vision at a distance of 33cm before and one hour after instillation of 1.25% pilocarpine eye drop.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hamideh Sabbaghi
🇮🇷Tehran, Iran, Islamic Republic of